secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vanda Pharmaceuticals Inc. (VNDA)
CIK:        0001347178
Form:       8-K
Filed at:   2022-11-02T23:59:59+00:00
Accession:  0001628280-22-027812
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vanda Q3 2022 revenue $65.3M (-7% YoY); net income $3.3M; narrows full-year guidance
--------------------------------------------------------------------------------

- Q3 total revenues $65.3M, down 7% from $70.1M; HETLIOZ sales $41.3M (-9%), Fanapt $24.0M (-2%).
- Net income $3.3M ($0.06 diluted EPS) vs $7.8M ($0.14) a year ago; first nine months net loss $0.6M.
- Full-year 2022 revenue guidance narrowed to $240-270M (from $240-280M); year-end cash forecast >$450M.
- Cash, cash equivalents and marketable securities $454.8M as of Sept 30, up $48.8M YoY.
- Pipeline: sNDA for HETLIOZ in insomnia expected by end-2022; NDA for tradipitant in gastroparesis expected H1 2023; Fanapt bipolar Phase III fully enrolled, results by end-2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347178/000162828022027812/0001628280-22-027812-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347178/000162828022027812/vnda-20221102.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-027812

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer